US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with EvolveImmune Therapeutics, Inc., an immunotherapy platform company backed by industry giants including Pfizer (NYSE: PFE) and BMS (NYSE: BMY). The partnership will focus on leveraging EvolveImmune’s T-cell engager platform to develop novel antibody-based therapies for the treatment of solid and hematologic malignancies.
EvolveImmune’s proprietary EVOLVE platform is engineered to deliver potent, selective, and integrated T-cell co-stimulation, which amplifies and sustains the tumor-killing capacity of T-cells. This innovative approach aims to address therapeutic challenges in solid and hematologic tumors by bypassing low tumor immunogenicity, conditionally activating adaptive immunity, and reducing T-cell dysfunction.
As per the terms of the agreement, EvolveImmune will receive an upfront fee and equity investment totaling USD 65 million from AbbVie and is eligible for up to USD 1.4 billion in additional option fees and milestones, along with tiered royalty payments on net sales.- Flcube.com
